Tim Wang, CFA

Chief Business Officer @ Duality Biologics

About

Tim Wang, CFA, currently leads business development and strategy at DualityBio. Based in New Jersey, Tim is a seasoned finance professional with deep expertise across healthcare investment research, banking, and pharmaceutical strategy/business development. A research scientist by training, Tim generated five issued U.S. patents on drug discovery while at a major pharma company. Tim was a former member of top-ranked equity research teams to cover U.S. major pharmaceutical and life science industries at three top Wall Street firms. Tim's banking career spanned 15 years in cross-border healthcare research and advisory at a leading global financial institution.

Country

United States

City

Edison

Industry

Biotechnology

Skill

Business Development, Research and analysis, Investments, Equity Research, Financial Modeling, Valuation, Financial Analysis, Investment Banking, Lifesciences, Private Equity, Life Sciences, Capital Markets, Medical Devices, Equities, Hedge Funds, Venture Capital, Biochemistry, Healthcare, Analysis, Research

Experience

Chief Business Officer

Duality Biologics

2022-6 - Present · 4 yrs 3 mos

United States

Lead business development and strategy

Executive Director, U.S. Healthcare Research and Advisory

Mizuho

2007-3 - 2021-9 · 14 yrs 7 mos

New York, New York, United States

Covered U.S. healthcare industry, including pharmaceuticals, biotech, medical device and diagnostics as a part of banking division. Attended hundreds of industry, medical and broker conferences to stay current of new development. Analyzed industry trends and researched individual companies to uncover insights. Expert in pharmaceutical strategy and many therapeutic areas, especially oncology, regenerative medicine, autoimmune, orphan, and other TAs. Provided M&A, business development and other strategic advice to corporate clients. Worked in conjunction with bankers to serve corporate clients' banking needs. Had extensive strategic dialog with many U.S. and Japanese biopharma and healthcare companies.

Associate Research Analyst

UBS

2004-5 - 2007-3 · 2 yrs 11 mos

New York, New York, United States

A member of top-ranked large-cap pharmaceutical research team. Provided equity research coverage of U.S. Pharmaceutical companies, including PFE, MRK, LLY, BMY, SGP, and WYE. Analyzed industry trend and individual companies. Communicated stock recommendation to clients. Researched and published on global pharmaceutical industry strategy.

Associate

J.P. Morgan

2004-3 - 2004-5 · 3 mos

New York, New York, United States

A member of a #1 ranked large-cap pharmaceutical research team. Provided equity research coverage of U.S. pharmaceutical companies, including PFE, MRK, LLY, BMY, SGP, and WYE.

Associate

Thomas Weisel Partners

2003-1 - 2004-3 · 1 yr 3 mos

New York, New York, United States

Equity research coverage of U.S. life science and diagnostic companies, including IVGN, AFFX, ABI, MIL, TMO, VARI, PKI, FSH, CRL, WAT, etc. Financial analysis and modeling. Technology assessment. Communicated investment recommendations to clients.

Research Scientist

Schering-Plough Research Institute

1997-10 - 2002-12 · 5 yrs 3 mos

Kenilworth, New Jersey, United States

Conducted research in Infectious Disease and Tumor Biology group of Schering-Plough Research Institute. Inventor of five patents that cover the discovery and characterization of 30-40 genes involved in biosynthesis of an antibiotics. Published several research articles in peer-reviewed journals. Worked 3 months in the finance group of SPRI, helping manage capital investment projects of the institute.

Summer intern

Amgen

1997-6 - 1997-8 · 3 mos

Thousand Oaks, California, United States

Worked in the neuroscience department at Amgen as a intern researcher. Identified neuropepetide receptor subtypes in fugu fish.

Education

NYU Stern School of Business

Finance/Marketing

2000-1 - 2002-12 · 3 yrs

Majors in Finance and Marketing. GPA: 3.98 · Awarded "The Leonard N. Stern School of Business Alumni Association Award for highest achievement and scholastic attainment" · Awarded The Dean's Award for outstanding scholarship · Awarded "The Money Marketers Marcus Nadler Award for attaining the highest scholastic ranking in the area of banking and finance" · Awarded "The Hector Lazo Memorial Award in Marketing"

University of Southern California

Biochemistry

1996-9 - 1997-5 · 9 mos

Completed 24 credit courses in the Ph.D. program. Worked on mammalian gene expression project at Norris Cancer Center.

The University of British Columbia

Biochemistry

1994-9 - 1996-5 · 1 yr 9 mos

Worked on a research project studying rRNA processing in archaebacteria. Published one paper on this subject. Attended two scientific conferences and hundreds of research seminars.